Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by Carnegie Investment Counsel

Carnegie Investment Counsel boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 25.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 376,910 shares of the company's stock after purchasing an additional 76,650 shares during the quarter. Carnegie Investment Counsel owned about 0.17% of Hims & Hers Health worth $9,114,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of HIMS. State Street Corp grew its holdings in shares of Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock worth $85,221,000 after purchasing an additional 206,078 shares during the period. Geode Capital Management LLC boosted its position in Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock worth $79,029,000 after purchasing an additional 482,177 shares during the period. Wellington Management Group LLP boosted its position in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock worth $63,446,000 after purchasing an additional 883,230 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company's stock valued at $30,714,000 after purchasing an additional 218,566 shares in the last quarter. Finally, Verition Fund Management LLC raised its position in Hims & Hers Health by 15.0% in the third quarter. Verition Fund Management LLC now owns 645,731 shares of the company's stock valued at $11,894,000 after purchasing an additional 84,316 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company's stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 188,888 shares of the business's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now directly owns 67,015 shares of the company's stock, valued at approximately $1,399,273.20. This trade represents a 73.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,080,208 shares of company stock worth $29,106,823 over the last quarter. 17.71% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on HIMS. Piper Sandler upped their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research report on Wednesday, November 6th. Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Monday, January 6th. Finally, TD Cowen reaffirmed a "buy" rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $25.13.

Hims & Hers Health Stock Down 0.5 %

Shares of HIMS traded down $0.14 during mid-day trading on Friday, hitting $27.80. The stock had a trading volume of 18,842,443 shares, compared to its average volume of 10,492,087. The company has a market cap of $6.07 billion, a PE ratio of 63.19 and a beta of 1.31. Hims & Hers Health, Inc. has a fifty-two week low of $8.14 and a fifty-two week high of $35.02. The company's fifty day simple moving average is $27.60 and its two-hundred day simple moving average is $21.80.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. The firm's revenue for the quarter was up 77.1% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.